LouisAdrianVandermolenMD

PubMed

• 16 citations
  Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic melanoma?
  Robert O. Dillman, Neil M. Barth, Louis A. VanderMolen, Khosrow Mahdavi, Stephanie E. McClure> ;Cancer Biotherapy & Radiopharmaceuticals. 2012 Jul 17
• 2 citations
  A retrospective study of induction chemotherapy with docetaxel, cisplatinum, and 5-fluorouracil followed by concurrent radiotherapy with cetuximab in locally advanced ...
  Brian S. Kim, Robert O. Dillman, Peter Chen, Russell Hafer, Craig Cox, Neil M. Barth, R. Matthew Carroll, Louis A. VanderMolen, Minh Nguyen, JinChu Huang, Annamarie Mi...> ;American Journal of Otolaryngology. 2012 Jan 1
• 7 citations
  Should High-Dose Interleukin-2 Still be the Preferred Treatment for Patients with Metastatic Renal Cell Cancer?
  Robert O. Dillman, Neil M. Barth, Louis A. VanderMolen, Warren H. Fong, Khosrow Mahdavi, Stephanie E. McClure> ;Cancer Biotherapy & Radiopharmaceuticals. 2011 Jul 5
• 8 citations
  High-dose chemotherapy and autologous stem cell rescue for metastatic breast cancer: superior survival for tandem compared with single transplants.
  Robert O. Dillman, Neil M. Barth, Louis A. VanderMolen, Kanoe Allen, Linda D. Beutel, Sherri Chico> ;American Journal of Clinical Oncology. 2005 Jun 1
• 16 citations
  Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma.
  Robert O. Dillman, Neil M. Barth, Louis A. VanderMolen, Khosrow Mahdavi, Linda D. Beutel, Cristina de Leon, Carol DePriest, Shankar K. Nayak> ;Cancer Biotherapy & Radiopharmaceuticals. 2004 Nov 15
• 6 citations
  Does continuous-infusion interleukin-2 increase survival in metastatic melanoma?
  Robert O. Dillman, Audrey A. O'Connor, Linda Simpson, Neil M. Barth, Louis A. VanderMolen, Peter Vanderplas> ;American Journal of Clinical Oncology. 2003 Apr 1
• Successful treatment of transitional cell carcinoma of the urethra with chemotherapy.
  Louis A. VanderMolen, P. F. Sheehy, Robert O. Dillman> ;Cancer Investigation. 2002 Sep 4
• 19 citations
  Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma.
  Robert O. Dillman, Neil M. Barth, Louis A. VanderMolen, David H. Garfield, Cristina de Leon, Audrey A. O'Connor, Khosrow Mahdavi, Shankar K. Nayak> ;Cancer Biotherapy & Radiopharmaceuticals. 2001 Feb 1
• 23 citations
  Hybrid high-dose bolus/continuous infusion interleukin-2 in patients with metastatic melanoma: a phase II trial of the Cancer Biotherapy Research Group (formerly the N...
  Robert O. Dillman, Michael C. Wiemann, Louis A. VanderMolen, Martin J. Bury, Carol DePriest, C. Church> ;Cancer Biotherapy & Radiopharmaceuticals. 1997 Aug 1
• 15 citations
  Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
  Barry L. Gause, M Sznol, William C. Kopp, John E. Janik, Ronald G. Steis, W J Urba, William Sharfman, Robert G. Fenton, S P Creekmore, Jon Holmlund, Kevin C. Conlon, L...> ;Journal of Clinical Oncology. 1996 Aug 1
• 27 citations
  Malignant melanoma and pregnancy ten questions.
  Robert O. Dillman, Louis A. VanderMolen, Neil M. Barth, K J Bransford> ;The Western Journal of Medicine. 1996 Feb 1
• 3 citations
  The integration of high-dose chemotherapy and biotherapy: initial 5-year experience with autologous bone marrow transplantation in a comprehensive community cancer cen...
  Robert O. Dillman, Neil M. Barth, Khosrow Mahdavi, Louis A. VanderMolen, Shankar K. Nayak, Audrey A. O'Connor> ;Cancer Biotherapy. 1995 Jan 1
• 16 citations
  High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer.
  Eddie Reed, John E. Janik, Michael A. Bookman, Mace Rothenberg, Justine R. Smith, Robert C. Young, Robert F. Ozols, Louis A. VanderMolen, Elise C. Kohn, Joan Jacob> ;Journal of Clinical Oncology. 1993 Nov 1
• 4 citations
  Primary Lymphoma of the Kidney: Complete Remission After Systemic Chemotherapy
  Louis A. VanderMolen, Robert O. Dillman> ;Journal of the National Cancer Institute. 1993 Mar 17
• 27 citations
  Pilot Study of Interleukin-2 and Lymphokine-Activated Killer Cells Combined With Immunomodulatory Doses of Chemotherapy and Sequenced With Interferon Alfa-2a in Patien...
  M Sznol, Jeffrey W. Clark, Ronald G. Steis, Walter J. Urba, Larry Rubinstein, Louis A. VanderMolen, John E. Janik, William H. Sharfman, Robert G. Fenton, Stephen P. Cr...> ;Journal of the National Cancer Institute. 1992 Jun 17
• 87 citations
  Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity.
  Ronald G. Steis, W J Urba, Louis A. VanderMolen, Michael A. Bookman, Jeffrey W. Clark, R L Miller, E D Crum, S K Beckner, J E McKnight> ;Journal of Clinical Oncology. 1990 Oct 1
• 4 citations
  Erythrocytosis in hairy cell leukaemia following therapy with interferon alpha.
  Ronald G. Steis, Louis A. VanderMolen, Jeffry B. Lawrence, Garwin K. Sing, Frank Ruscetti, Walter J. Urba, Jeffrey W. Clark, Dan L. Longo> ;British Journal of Haematology. 1990 May 1
• 3 citations
  Surface light chain phenotype in indolent lymphomas: lack of prognostic significance.
  Louis A. VanderMolen, P L Duffey, Jeffrey Cossman, Elaine S. Jaffe, Dan L. Longo> ;American Journal of Hematology. 1990 May 1
• 34 citations
  Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Advanced Malignancy: A Phase Ib Trial
  Ronald G. Steis, Louis A. VanderMolen, Dan L. Longo, Jeffrey W. Clark, William C. Kopp, Francis W. Ruscetti, Stephen P. Creekmore, Lori J. Elwood, Jean C. Hursey, Walt...> ;Journal of the National Cancer Institute. 1990 Apr 18
• 17 citations
  Diffuse osteosclerosis in hairy cell leukemia
  Louis A. VanderMolen, Walter J. Urba, Dan L. Longo, Jeffry B. Lawrence, Harvey R. Gralnick, Ronald G. Steis> ;Blood. 1989 Nov 1
• 18 citations
  Use of prophylactic antibiotics for prevention of intravascular catheter-related infections in interleukin-2-treated patients.
  Lynn C. Hartmann, Walter J. Urba, Ronald G. Steis, Louis A. VanderMolen, Stephen P. Creekmore, Mario Sznol, Manuel A. Casciano, Nancy Engler, Dan L. Longo> ;Journal of the National Cancer Institute. 1989 Aug 2
• 7 citations
  Adrenal Insufficiency and Interleukin-2 Therapy
  Louis A. VanderMolen, Dan L. Longo, Ronald G. Steis, Peter Kremers, Mario Sznol> ;Annals of Internal Medicine. 1989 Jul 15
• 7 citations
  Hypothyroidism after interleukin-2 therapy.
  Lynn C. Hartmann, W J Urba, Ronald G. Steis, Louis A. VanderMolen, S P Creekmore, Dan L. Longo> ;Journal of Clinical Oncology. 1989 May 1
• 7 citations
  Lactic acidosis in lymphoma: prompt resolution of acidosis with therapy directed at the lymphoma.
  Louis A. VanderMolen, Sandra M. Swain, Dan L. Longo> ;Journal of the National Cancer Institute. 1988 Sep 7
• 7 citations
  Ringed sideroblasts in primary myelodysplasia. Leukemic propensity and prognostic factors.
  Louis A. VanderMolen, Lawrence Rice, Mary Ann Rose, Edward C. Lynch> ;Archives of Internal Medicine. 1988 Mar 1
• Join now to see all